Autonomic Nervous System Pharmacology: A Comprehensive Overview

Introduction

The autonomic nervous system (ANS) controls involuntary functions of the body. It is divided into two branches that act on the same organs but produce opposite effects: - Parasympathetic nervous system (PSNS) – “rest‑and‑digest” (purple in the video). - Sympathetic nervous system (SNS) – “fight‑or‑flight” (green in the video).

Basic Anatomy & Physiology

• Origins: PSNS fibers arise from cranial (III, VII, IX, X) and sacral (S2‑S4) nerves; SNS fibers arise from thoracic (T1‑T12) and lumbar (L1‑L3) segments (thoracolumbar). No autonomic fibers originate from the cervical spine.
• General rule: Both branches innervate the same target organs, but their actions are opposite. Exceptions:
• Vasculature is innervated only by the SNS.
• Sweat glands receive input from both branches.
• Physiological examples:
• Eyes – SNS dilates pupils (mydriasis); PSNS constricts pupils (miosis).
• Mouth – SNS causes dry mouth; PSNS stimulates salivation.
• Heart – SNS increases rate and contractility; PSNS decreases them.
• Airways – SNS bronchodilation; PSNS bronchoconstriction.
• GI tract – SNS inhibits peristalsis; PSNS promotes digestion.
• Bladder – SNS relaxes detrusor muscle (holds urine); PSNS contracts it (allows voiding).

Receptor Classifications

• Ionotropic receptors – ligand‑gated ion channels (e.g., nicotinic ACh receptors). Activation opens the channel for Na⁺, Ca²⁺, etc.
• Metabotropic receptors – G‑protein‑coupled receptors (GPCRs). Activation triggers second‑messenger cascades (cAMP, IP₃, Ca²⁺).

Cholinergic Receptors (ACh)

• Nicotinic (N) – ionotropic, found at autonomic ganglia and the neuromuscular junction. Binds ACh and nicotine.
• Muscarinic (M1‑M5) – metabotropic, mediating PSNS effects.
• M2 – heart: ↓ SA/AV node activity → bradycardia.
• M3 – smooth muscle: relaxation of bronchi, bladder, GI tract; stimulates glandular secretions.
• Mnemonic for PSNS actions: SLUDD + BAMS (Salivation, Lacrimation, Urination, Defecation, Diaphoresis; Bronchoconstriction, Abdominal cramps, Mydriasis).

Adrenergic Receptors (Catecholamines)

• Alpha‑1 – vascular smooth‑muscle contraction → vasoconstriction, pupil dilation, urinary retention.
• Alpha‑2 – primarily central; activation inhibits sympathetic outflow (used therapeutically to lower BP).
• Beta‑1 – heart: ↑ rate, contractility, renin release.
• Beta‑2 – bronchodilation, vasodilation in skeletal muscle, uterine relaxation.

Pharmacology of the Parasympathetic System

• Muscarinic Agonists (non‑selective): mimic ACh → stimulate all M receptors. Contra‑indicated in peptic ulcer, asthma/COPD, and congestive heart failure.
• Direct‑acting Muscarinic Agonists: e.g., pilocarpine (used in dentistry to increase salivation).
• Indirect‑acting Agents: cholinesterase inhibitors (e.g., neostigmine, physostigmine) prevent ACh breakdown, enhancing parasympathetic tone. Toxic irreversible inhibitors (organophosphates) are treated with pralidoxime.
• Muscarinic Antagonists (anticholinergics): block M receptors, producing opposite of PSNS (e.g., atropine, scopolamine).
• Ganglionic Blockers (nicotinic antagonists): block autonomic ganglia (e.g., trimethaphan). Can cause profound hypotension.
• Neuromuscular Blocking Agents: target nicotinic receptors at the skeletal‑muscle junction (e.g., vecuronium, succinylcholine) – listed for completeness.

Pharmacology of the Sympathetic System

• Adrenergic Agonists:
• Direct: epinephrine, norepinephrine, isoproterenol – stimulate α/β receptors depending on dose.
• Indirect: release stored NE (e.g., ephedrine, phenylephrine), inhibit reuptake (e.g., tricyclic antidepressants, SNRIs), or inhibit MAO (e.g., phenelzine).
• Adrenergic Antagonists (beta‑blockers): block β receptors, reducing heart rate and contractility (e.g., propranolol, metoprolol). Some agents also block α receptors (e.g., prazosin, phentolamine).
• Sympathomimetics vs. Sympatholytics:
• Sympathomimetics mimic SNS activity (increase NE/EPI availability or directly stimulate receptors).
• Sympatholytics blunt SNS activity (α‑2 agonists like clonidine, methyldopa act centrally to reduce sympathetic outflow).
• Special Concepts:
• Epinephrine reversal – when an α‑blocker is present, epinephrine’s β₂‑mediated vasodilation dominates, producing net vasodilation.
• Vasovagal reflex – excessive vagal (parasympathetic) activation leads to bradycardia and hypotension, causing fainting; can be countered acutely with anticholinergics such as atropine.

Clinical Pearls for the Board Exam

1. Remember the opposing actions of M₂ vs. β₁ on the heart.
2. Alpha‑2 agonists paradoxically produce a sympathetic block because they act centrally.
3. Epinephrine reversal occurs with concurrent α‑blockade.
4. SLUDD + BAMS helps recall parasympathetic target organ effects.
5. Distinguish ionotropic (nicotinic) vs. metabotropic (muscarinic/adrenergic) receptors when predicting drug actions.

Study Tips

• Sketch the color‑coded diagram (purple = PSNS, green = SNS) and label pre‑ganglionic vs. post‑ganglionic fibers.
• Use the mnemonics SLUDD + BAMS and M‑receptor functions (M2‑heart, M3‑smooth muscle).
• Group drugs by mechanism (direct agonist, indirect agonist, antagonist, enzyme inhibitor) rather than memorizing long lists.
• Practice clinical scenarios (e.g., treating bradycardia with atropine, managing organophosphate poisoning with pralidoxime).

This article condenses the video’s content into a self‑contained study guide, so you can grasp autonomic pharmacology without watching the original footage.

Understanding the opposing roles of the parasympathetic and sympathetic systems, the receptor families they use, and how drugs modulate these pathways is essential for both clinical practice and board exams.